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Adult onset pompe disease is a genetic disorder characterized by slowly progressive skeletal and 
respiratory muscle weakness. symptomatic patients are treated with enzymatic replacement therapy 
with human recombinant alfa glucosidase. Motor functional tests and spirometry are commonly used 
to follow patients up. However, a serological biomarker that correlates with the progression of the 
disease could improve follow-up. We studied serum concentrations of tGFβ, pDGF-BB, pDGF-AA 
and CTGF growth factors in 37 adult onset Pompe patients and 45 controls. Moreover, all patients 
performed several muscle function tests, conventional spirometry, and quantitative muscle MRI using 
3-point Dixon. We observed a statistically significant change in the serum concentration of each growth 
factor in patients compared to controls. However, only PDGF-BB levels were able to differentiate 
between asymptomatic and symptomatic patients, suggesting its potential role in the follow-up of 
asymptomatic patients. Moreover, our results point to a dysregulation of muscle regeneration as an 
additional pathomechanism of pompe disease.
Pompe disease is an autosomal recessive disorder produced by mutations in the GAA gene, which codifies the 
enzyme acid alpha-glucosidase1. This enzyme metabolizes glycogen to glucose inside the lysosomes of the cells. 
A lack of it leads to an accumulation of glycogen in body tissues such as liver, neurons, smooth, skeletal or car-
diac muscle2. Pompe disease has a wide clinical spectrum ranging from the classical infantile disease (IOPD) to 
late onset phenotype. IOPD patients develop a quickly progressive disease characterized by generalized muscle 
weakness and hypertrophic cardiomyopathy, leading to death in the first year of life if left untreated3. Enzymatic 
replacement therapy with alfa-glucosidase (ERT) is started as early as possible, because IOPD is life-threatening 
disorder and ERT clearly change patients’ clinical condition4,5.
In contrast, adult onset Pompe patients (AOPD) can have heterogeneous clinical presentations, ranging from 
isolated hyperckemia to weakness involving the respiratory, axial, pelvic and scapular girdle muscles6,7. Natural 
history studies suggest that muscle weakness in AOPD progresses very slowly. In some cases, patients develop 
subtle muscle symptoms, such as postural abnormalities or a change in their walking pattern, that do not influ-
ence general motor function and can therefore delay medical consultation8,9. Unlike the procedure for IOPD, 
guidelines recommend starting ERT in AOPD only if muscle or respiratory weakness is detected in clinical exam-
ination10. In fact, asymptomatic AOPD patients are currently followed up using different muscle function tests 
to try to identify changes in motor performance that could lead to the initiation of treatment11. However, it is 
possible that the process of muscle degeneration and fibro-fatty substitution, which is irreversible, could have 
started without yet producing significant changes in motor functional tests12. Moreover, it is not certain that 
common muscle function tests, such as the 6 minute walking test (6MWT), are precise enough to detect slight 
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changes in motor performance13. For these reasons, having a serum growth factor able to identify patients in 
which fibro-fatty substitution has begun, would be of great utility14,15.
The main aim of our research was to study the serum concentration of a group of growth factors related 
to muscle fibrosis, degeneration and inflammation, in a cohort of 37 symptomatic and asymptomatic AOPD 
patients. We compared the serum concentration of Pompe patients with a control group. We also studied whether 
there were differences in the serum concentration of these growth factors between symptomatic and asympto-
matic patients. In parallel, we evaluated the patients using several motor function tests, spirometry, quantitative 
muscle MRI (qMRI), and patient-reported outcome measures (PROMs), in order to establish whether or not a 
correlation between serum concentration and the clinical situation of the patients exists.
Results
Description of the cohort. 37 AOPD patients were included in the study. Twenty-nine patients were symp-
tomatic (18 women, 62.1%) and 8 were asymptomatic. Twenty-three of the 29 symptomatic patients were already 
receiving ERT when first sample was obtained. In the remaining 6 symptomatic patients, blood samples were 
obtained before ERT was started. Asymptomatic patients were studied in neuromuscular disorder units because 
high levels of hepatic enzymes or CKs were found in random checkup blood analyses (5 cases) or because they 
had relatives already diagnosed with Pompe disease (3 cases). The demographic and clinical data of these two 
groups are described in Table 1. Results of the motor function tests and muscle MRI of the Pompe cohort has been 
already reported15,16. We compared the ELISA results with serums obtained from age- and sex-matched controls 
(n = 45).
Growth factor serum levels in pompe patients compared to controls. Our first aim was to study 
whether there were differences in growth factor serum levels between Pompe patients and controls. We observed 
significant differences in PDGF-BB, TGF-β, PDGF-AA and CTGF levels as is shown in Fig. 1. Serum PDGF-BB 
and TGF-β1 levels were significantly lower in Pompe patients compared to the control group. In the case of 
PDGF-BB, the median and interquartile range (IQR) value of Pompe serum levels were of 1.739 ng/ml (IQR: 
1.467–2.186) compared to 2.360 ng/ml (IQR: 1.494–3.23) in controls (Mann-Whitney U test, p = 0.047). In the 
case of TGF-β1, Pompe median serum levels were of 46.17 ng/ml (IQR: 36.34–55.48) compared to 55.05 ng/ml 
(IQR: 46.79–64.8) in controls (Mann-Whitney U test, p = 0.007). However, serum PDGF-AA and CTGF levels 
were significantly higher compared to control samples. In the case of PDGF-AA, the median Pompe serum levels 
were 2630 ng/ml (IQR: 2161–3399) compared to 2242 ng/ml (IQR: 1642–3051) in controls (Mann-Whitney U 
test, p = 0.01). And in the case of CTGF, median Pompe serum levels were of 3.831 ng/ml (2.917–4.999) compared 
to 2.589 ng/ml (1.503–4.013) in controls (Mann-Whitney U test, p = 0.023).
PDGF-BB levels differentiate between symptomatic and asymptomatic Pompe patients. Our 
second aim was to assess whether any of the growth factors studied was able to differentiate between asymp-
tomatic and symptomatic Pompe patients (Fig. 2). We observed that PDGF-BB levels were significantly lower 
in symptomatic patients (Median: 1.565 ng/ml (IQR: 1.405–2.096) compared to asymptomatic Pompe patients 
(Median: 2.038 ng/ml (IQR: 1.907–3.803) (Mann-Whitney U test, p = 0.044) (Fig. 2A). In contrast, we did not 
identify differences in TGF-β1, CTGF and PDGF-AA serum concentration between symptomatic and asympto-
matic patients.
As there were significant differences in age between symptomatic and asymptomatic Pompe patients (Table 1), 
we decided to add a new group of young controls with a mean age of 23 years. We observed significant differences 
in PDGF-BB serum levels between symptomatic Pompe patients and all other groups, including young controls 
(mean age = 23 years old) (Mann-Whitney U test, p = 0.0012), all controls and asymptomatic Pompe patients. 
We did not observe significant differences between controls of different ages and between asymptomatic Pompe 
patients and young controls (Mann-Whitney U test, p > 0.05) (Fig. 3).
To further analyze whether PDGF-BB serum levels were useful for differentiating between symptomatic or 
asymptomatic patients, we used a receiver operating characteristics curve, or ROC curve, and analyzed area 
under the curve (AUC). The ROC curve (AUC: 0.737, p = 0.042, 95%CI: 0.539–0.935) (Fig. 4) confirmed that 
PDGF-BB levels were able to predict which patients were symptomatic and which were asymptomatic. Therefore, 
Patients
Symptomatic Asymptomatic p*
Number of patients 29 8
Gender (W) 18, 62.1% 4, 50% 0.21
Age at baseline 51 (31–65) 21 (8–51) 0.001
Time from onset of symptoms 17 (4–42)
Patients on ERT 22 —
Time on ERT 4.3 (1–9) —
Aids for walking 10 —
Ventilation 13 —
Table 1. Demographic and clinical data of Pompe patients. Comparisons between symptomatic and 
asymptomatic patients are shown with p-value. P was considered significant if lower than 0.05.
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patients with lower values than the cut-off level (1.97 ng/ml) had a higher probability of being asymptomatic. 
Sensitivity and specificity were 75% and 76% respectively.
pDGF-BB levels decrease in pompe patients but not in other muscle dystrophies. Since the 
function of PDGF-BB seems to be related with muscle regeneration, we analyzed serum levels of this growth 
factor in other muscle dystrophies in which regeneration increases, such as Duchenne muscle dystrophy (DMD), 
Becker muscle dystrophy (BMD) dysferlinopathy (DYSF) and facioscapulohumeral muscular dystrophy (FSH). 
Clinical and demographic features of these groups are described in Table 2.
We observed that PDGF-BB levels were significantly higher in DMD (Median: 3.14 ng/ml (IQR: 1.6–6.76) 
(Mann-Whitney U test, p = 0.0469) and BMD (Median: 3.681 ng/ml (IQR: 2.945–4.398) (Mann-Whitney U test, 
p = 0.0077) compared to controls. We also obtained significant differences in DMD, BMD and FSH (Median: 
3.656 ng/ml (IQR: 1.944–5.443) (Mann-Whitney U test, p = 0.0052) compared to Pompe disease (DMD: 
Mann-Whitney U test, p = 0.0065; DMB: Mann-Whitney U test, p = 0.0001) (Fig. 5).
Correlation between pDGF-BB serum levels and results of muscle function tests and quantitative 
muscle MRI. We used the Spearman test to identify if there were any correlations between PDGF-BB serum 
concentration and the results of the muscle function tests, spirometry, patient-reported outcomes and qMRI. As 
it is shown in Table 3, we did not find any significant correlation. However, we found a non-significant tendency 
between PDGF-BB levels and 6MWT, the MRC score, the Myometry score, MIP, and thigh fat fraction measured 
using 3 point Dixon MRI.
Discussion
In the present study, we found significant differences in the serum concentration of four growth factors related to 
the process of skeletal muscle degeneration and regeneration in AOPD patients compared to controls. However, 
only serum levels of PDGF-BB were significantly different when symptomatic patients were compared with 
asymptomatic patients. In fact, the diagnostic accuracy of the PDGF-BB concentration to distinguish between 
symptomatic and asymptomatic patients was assessed by ROC curves, determining an optimal cut-off value of 
1.97 ng/ml.
Figure 1. Serum levels of different cytokines in control group and pompe group. (A) PDGF-BB levels, (B) TGF-β1, 
(C) PDGF-AA and (D) CTGF levels were measured. Variables are represented as median and interquartile range 
(IQR). Statistical significance of the results by Mann-Whitney test: *p ≤ 0.05 and **p ≤ 0.01.
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Figure 2. Serological levels of four growth factors in three different groups: control, symptomatic Pompe 
patients and asymptomatic Pompe patients. (A) PDGF-BB levels, (B) TGF-β1, (C) PDGF-AA and (D) CTGF 
levels were measured. Variables are represented as median and interquartile range (IQR). Comparisons were 
made using Mann-Whitney test. Statistical significance of the results; *p ≤ 0.05 and **p ≤ 0.01.
Figure 3. Serological levels of PDGF-BB in different groups: control, young controls, asymptomatic and 
symptomatic Pompe patients. Variables are represented as median and interquartile range (IQR). Comparisons 
were made using Mann-Whitney test. Statistical significance of the results; *p ≤ 0.05 and **p ≤ 0.01.
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It is well known that chronic muscle damage leads to persistent inflammatory infiltration, muscle necrosis 
and activation of fibro/adipogenic progenitor (FAP) cells17, something that has been studied in dystrophic mus-
cles. Eventually, muscle fibers are lost and substituted by fibro-adipose tissue18. Several growth factors have been 
related with this process, including those in the present study. TGF-β1 and PDGF-BB play an important role in 
satellite cell proliferation and fibrotic remodeling19–21. TGF-β1 is crucial in the initiation of fibrosis in skeletal 
Figure 4. Receiver-operator characteristic (ROC) curve of the PDGF-BB for distinguishing symptomatic and 
asymptomatic patients. The area under the curve (AUC) for PDGF-BB was 0.737 with a P value of 0.042 and 
95% confidence interval (CI) were 0.539–0.935).
DMD (n:11) BMD (n:10) Dysferlinopathy (n:8) FSHD (n:10) Pompe (n:37)
Age 11.75 y.o 32.93 y.o. 35.92 y.o. 49.62 y.o. 34.5 y.o
Gender 11 men 10 men 4 men 6 men 15 men
Unassited walk 7 3 4 6 27
Aids for walking 4 3 4 4 10
Ventilator 1 1 0 1 13
Table 2. Demographic and clinical data of patients with muscle disorders included in this report. DMD: 
Duchenne muscle dystrophy; BMD: Becker muscle dystrophy; FSHD: facioscapulohumeral muscle dystrophy; 
y.o.: years old.
Figure 5. Serum levels PDGF-BB in muscle dystrophies: Pompe, Duchenne muscle dystrophy (DMD), Becker 
muscle dystrophy (BMD), dysferlinopathy (DYSF) and facioscapulohumeral muscular dystrophy (FSH). 
Variables are represented as median and interquartile range (IQR). Statistical significance of the results by 
Mann-Whitney test: *p ≤ 0.05, **p ≤ 0.01and ***p ≤ 0.001.
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muscle20–22, and PDGF-AA enhances the process of fibro-adipogenic expansion regulated by FAP cells23–26. 
CTGF influences the fibrotic process by inducing the expression and release of collagen type 1 by activated fibro-
blasts26–28. Although the process of muscle degeneration has been well established in animal models of muscular 
dystrophies such as Duchenne muscle disease, it is not yet completely known whether it happens in the same way 
as in Pompe disease. However, radiological studies show that skeletal muscle is gradually lost and substituted by 
fat tissue in patients with adult onset Pompe, mimicking what happens in patients with muscular dystrophies and 
suggesting a similar skeletal muscle degenerative process29–31. Based on this hypothesis, we decided to study the 
serum concentration of growth factors related with the process of muscle regeneration, degeneration and fibrosis.
PDGF-BB, which is secreted by inflammatory cells and skeletal muscle regenerative fibers, has recently 
been related with the process of muscle regeneration through the activation of satellite cell proliferation and 
chemotaxis32. We observed lower levels of serum PDGF-BB in AOPD patients compared to controls. Moreover, 
PDGF-BB serum concentration was even lower in symptomatic patients, suggesting a correlation with disease 
progression. As PDGF-BB probably influences muscle regeneration, the lower levels found in AOPD patients 
might reflect impaired regenerative response in Pompe disease, something that has also been suggested by 
other authors. Impaired satellite cell activation has been described in muscle samples from Pompe patients33–35. 
Moreover, serum levels of insulin growth-factor-1 and myostatin, two molecules related with the process of satel-
lite cell activation, are lower in serum of Pompe patients compared to controls36.
We did not observe a significant difference in serum levels of TGF-β1, PDGF-AA and CTGF in symptomatic 
compared to asymptomatic Pompe patients. These three factors have been related with the process of muscles 
fibrosis, as discussed early. The lower levels of TGF-β1 found in Pompe patients compared to controls, supports 
the idea that fibrosis is not a major issue in patients with Pompe disease. In fact, Dr. Palermo37 and collaborators 
did not find an up-regulation of TGFB1 fibrosis-associated genes in skeletal muscle Pompe patients, which sup-
ports our findings.
The lower levels of growth factors related to fibrosis and regeneration suggested by the current study could 
be explained by the lack of sarcolemma damage in Pompe disease. In most muscular dystrophies in which the 
process of muscle degeneration and regeneration has been studied, muscle damage is produced because of the 
instability of skeletal muscle membrane. Membrane tears induce a series of responses, such as the release by mus-
cle fibers of cytokines that recruit inflammatory cells and participate in the activation of satellite cells. Persistent 
inflammatory cells release profibrotic growth factors that lead to the expansion of fibrotic tissue. The process of 
muscle fiber degeneration in Pompe disease is probably different. There is no evidence of necrosis or inflamma-
tory infiltration38. As opposed to muscle membrane instability, lysosomal rupture has been proposed as the main 
mechanism leading to muscle fiber necrosis. Glycogen progressively accumulates in lysosomes producing their 
rupture and the release of lytic enzymes to the sarcoplasm, probably activating the process of autophagy38,39. It is 
tempting to hypothesize that local cell response is different in Pompe disease, with no recruitment of inflamma-
tory cells, no activation of satellite cells and no release of profibrotic factors. The fact that PDGF-BB levels were 
higher in serum samples from patients with other muscular dystrophies, and lower in Pompe disease, supports 
this hypothesis.
Test Spearman Correlation coefficient
Muscle function tests
6 MWT 0.055 0.33
Time to walk 10 meters 0.24
Timed up&go test 0.81
Time to climb 4 steps 0.17
Time to descend 4 steps 0.26
MRC score 0.07 0.31
Myometry score 0.07 0.31
MFM-20 0.77
Spirometry
CVF seated 1
CVF supine 0.28
MIP 0.057 −0.48
MEP 0.80
Patients reported outcomes
Activlim 0.84
SF36 0.80
INQoL 0.70
Quantitative muscle MRI
Thighs fat fraction 0.08 −0.28
Paraspinal fat fraction 0.2
Table 3. Correlation between PDGF-BB levels and results of the muscle function tests, spirometry, patients 
reported outcomes and qMRI. Spearman test was used to study if there was a correlation. P was considered 
significant if lower than 0.05. Correlation coefficient is shown for variables in which a tendency was found.
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The identification of growth factors useful for the follow-up of patients is considered one of the unmet needs 
in Pompe disease. ERT is being administered to those symptomatic patients, patients with muscle or respiratory 
muscle weakness. However, patients may develop mild motor disturbances, such as abnormal gait posture, due 
to the presence of mild axial involvement. Growth factors capable of differentiating between symptomatic and 
asymptomatic patients could then be a useful tool in follow-up. As we observed significant lower PDGF-BB 
levels in symptomatic Pompe patients than asymptomatic, we suggest PDGF-BB could be useful to monitorize 
progression of the disease and help to identify those patients in which the process of muscle degeneration has 
started without influencing muscle function yet. Other growth factors previously proposed, such as urine glucose 
tetrasaccharide Glc4 levels40,41, have utility in the diagnosis of Pompe disease, or in monitoring of the treatment 
but not for differentiating between symptomatic and asymptomatic patients42,43.
To summarize, we have identified a group of four growth factors related to the process of muscle degeneration 
and regeneration that are differently expressed in Pompe patients compared to controls. Interestingly, PDGF-BB 
levels were significantly different in symptomatic patients compared to asymptomatic. In our opinion, our results 
suggest that decreasing levels of PDGF-BB in asymptomatic patients should prompt us to tighten the follow-up 
of the patient, repeating muscle and respiratory function tests in order to consider starting ERT before muscle 
degeneration becomes irreversible.
Methods
patients and study design. This study is part of an ongoing prospective open-label study in which we are 
following up a group of symptomatic and non-symptomatic AOPD patients annually in our center using muscle 
function tests, muscle MRI and blood analysis. This study has been registered in Clinicaltrials.gov (identifier 
NCT01914536). The present research was performed in accordance with Spanish regulation for clinical trials and 
studies and following the recommendations described in the Declaration of Helsinki. The study was approved by 
The Ethical Committee of Hospital de la Santa Creu i Sant Pau (HSCSP) in Barcelona. All participants signed an 
appropriate informed consent form.
The diagnosis of Pompe disease was based on the presence of two mutations in the GAA gene. In cases where 
a single or no mutation was detected, diagnosis was based on reduced activity in at least two tissues, lymphocytes 
and skeletal muscle being the most common tissues studied, as has been recently suggested by the European 
Pompe Consortium10. All patients were considered adult onset since none of them developed symptoms before 
the age of 18.
We defined a patient as symptomatic when we identified muscle weakness in clinical examination using the 
Muscle Research Council score (MRC), or when Forced Vital Capacity (FVC), while seated, was lower than 
85%. A total of 37 patients were included: 23 symptomatic patients treated with ERT, 6 symptomatic patients 
untreated with ERT and 8 asymptomatic patients. All treated patients received 20 mg/kg acid alpha-glucosidase 
intravenously every other week. Untreated symptomatic patients were seen before starting ERT. Clinical and 
genetic features of this group of patients have been previously published15. In summary, mean age at baseline visit 
of the 23 symptomatic patients was 49.8 years old. 9 of these patients used sticks or wheelchair for walking, with 
two of them being fully wheelchair bound. 12 patients used non-invasive ventilation at night. Mean age of the 
6 non-treated symptomatic patients was 37.4 years old. Only one patient of this group used the stick for walk-
ing and one other patient required noninvasive ventilation at night. 8 presymtomatic AOPD patients were also 
included (mean age 21 years, 4 women). These patients were diagnosed of Pompe disease because they were rela-
tives of patients with Pompe or because the presence of high CK levels in blood samples. As controls we included 
45 patients whose age and sex matched our Pompe cohort (mean age 48 years, 29 women), and 10 more controls 
whose age and sex matched with asymptomatic Pompe patients (mean age 23 years, 6 women). The controls were 
volunteers, most of them relatives or caregivers of our Pompe patients that kindly agreed to participate in the 
study. CKs levels were normal in all control patients (Reference value for our laboratory is <174 U/L).
Growth factors identification. Blood samples were collected at baseline visit before motor function tests 
were performed. Blood was centrifuged for 1600 g for 9 minutes at 4 °C in order to separate the serum. The serum 
was aliquoted and stored at −80 °C until analysis.
Serum platelet-derived growth factor BB (PDGF-BB) and transforming growth factor β1 (TGF-β1) levels were 
measured using commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D, Minneapolis, MN, USA), 
according to the manufacturer’s instructions. A platelet-derived growth factor AA (PDGF-AA) human ELISA 
kit was provided by ThermoFisher (Thermo Fisher Scientific, Nepean, Canada) and connective tissue growth 
factor (CTGF) by EIAAB Science Co (Wuhan, China). Minimum detectable cytokine concentrations for these 
assays were measured to be 1.7 pg/ml for TGF-β1, 15 pg/ml for PDGF-BB, 40 pg/ml for PDGF-AA and 0.18 ng/ml 
for CTGF. Samples were measured in duplicate and read on a microplate reader Beckman Coulter AD 340 
(Beckam-Coulter, Brea, CA, USA) with AD-LD software.
Muscle function tests. All patients were evaluated by three physiotherapists (I.B., I.P. and E.M.), with expe-
rience in neuromuscular disorders, at HSCSP in Barcelona. Physiotherapists evaluated muscle function using 
the following tests: the 6MWT, time to walk 10 meters, timed up-and-go test, time to climb up and down 4 steps, 
and the 20 item motor function measure tool (MFM-20). Muscle strength was studied using both MRC and 
hand-held myometry. The MRC score was the sum of all individual MRC values, while the myometry score was 
the sum of all individual muscle values. ACTIVLIM, INQoL and SF-36 were used as patient-reported outcome 
measures. Forced vital capacity while seated and in a lying position, maximum inspiratory pressure (MIP) and 
maximum expiratory pressure (MEP) values were obtained with a Carefusion Microlab ML 3500 MK8 spirometer 
(Carefusion, Yorba Linda, CA, USA).
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Muscle imaging. All patients were examined in a Philips Achieva XR 1.5 Teslas located at HSCSP. We used 
the same positioning protocol for all patients: supine position with legs stretched, the patella facing upward and 
the ankles in a neutral position.
3D 3-point Dixon images were acquired with the following acquisition parameters: TR/TE = 5.78/1.8, 4 ms, 
flip angle = 15°, FOV = 520 × 340 × 300 mm, voxel size = 1 × 1 × 3 mm.
Analysis of the 3-point Dixon MR images was performed using the PRIDE (Philips Research Image 
Development Environment) tool, as has been reported previously15,42. ROIs were manually drawn on five slices 
of the following muscles: rectus femoris, vastus intermedius, vastus lateralis, vastus medialis, adductor magnus, 
sartorius, gracilis, semitendinosus and semimembranosus, and on three slices of biceps femoris long head, biceps 
femoris short head and adductor longus
Data analysis. Non-parametric tests were used for the statistical analysis of the variables. The Mann-Whitney 
U test investigated whether there were significant differences in variables between groups (symptomatic vs 
asymptomatic and control vs Pompe). We used Spearman’s rank correlation (coefficient reported as ρ) to inves-
tigate any correlation between the serum concentration of growth factors and the results of the muscle function 
tests, spirometry, quality of life scales and the thigh fat fraction obtained using qMRI. As we ran multiple cor-
relations, a Bonferroni test was performed to avoid type 1 errors. Finally, a ROC curve was performed to study 
whether PDGF-BB levels were able to differentiate between symptomatic and asymptomatic Pompe patients with 
high sensitivity and specificity. The results of all statistical studies were considered significant if P was lower than 
0.05. Statistical studies were performed using IBM SPSS® Statistics software version 21. The datasets generated 
during the current study are available from the corresponding author on reasonable request.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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